Parameter | p120ctn subcellular localisation (n = 133) | βctn subcellular localisation (n = 136) | ||||||||||
n | Normal (n = 10) | Reduced (n = 57) | Cytoplasm (n = 64) | Negative (n = 2) | p Value | n | Normal (n = 33) | Reduced (n = 53) | Cytoplasm (n = 42) | Negative (n = 8) | p Value | |
Tumour size (cm) | 2.66±1.09 | 2.59±1.25 | 3.14±1.88 | 1.35±0.21 | 0.136 | 2.18±0.98 | 2.69±1.27 | 3.26±1.95 | 4.50±1.83 | <0.001 | ||
Histological type | 133 | 0.017 | 136 | <0.001 | ||||||||
IDC, NOS | 89 | 8 (80%) | 40 (70.2%) | 41 (64.1%) | 0 (0%) | 94 | 24 (72.7%) | 43 (81.1%) | 25 (59.5%) | 2 (25%) | ||
ILC | 9 | 0 (0%) | 0 (0%) | 9 (14.1%) | 0 (0%) | 8 | 0 (0%) | 0 (0%) | 2 (4.8%) | 6 (75%) | ||
Medullary | 15 | 1 (10%) | 4 (7%) | 8 (12.5%) | 2 (100%) | 15 | 3 (9.1%) | 1 (1.9%) | 11 (26.1%) | 0 (0%) | ||
Tubular | 6 | 0 (0%) | 5 (8.8%) | 1 (1.5%) | 0 (0%) | 5 | 2 (6.1%) | 2 (3.8%) | 1 (2.4%) | 0 (0%) | ||
Mucinous | 7 | 1 (10%) | 3 (5.3%) | 3 (4.7%) | 0 (0%) | 7 | 2 (6.1%) | 5 (9.4%) | 0 (0%) | 0 (0%) | ||
Apocrine | 3 | 0 (0%) | 1 (1.7%) | 2 (3.1%) | 0 (0%) | 3 | 1 (3%) | 0 (0%) | 2 (4.8%) | 0 (0%) | ||
Papillary | 3 | 0 (0%) | 3 (5.3%) | 0 (0%) | 0 (0%) | 3 | 1 (3%) | 1 (1.9%) | 1 (2.4%) | 0 (0%) | ||
Cribriform | 1 | 0 (0%) | 1 (1.7%) | 0 (0%) | 0 (0%) | 1 | 0 (0%) | 1 (1.9%) | 0 (0%) | 0 (0%) | ||
Histological grade | 133 | 0.759 | 136 | 0.022 | ||||||||
Grade I | 18 | 1 (10%) | 10 (17.5%) | 7 (10.9%) | 0 (0%) | 17 | 5 (15.2%) | 5 (9.4%) | 3 (7.1%) | 4 (50%) | ||
Grade II | 42 | 4 (40%) | 16 (28.1%) | 22 (34.4%) | 0 (0%) | 42 | 13 (39.4%) | 16 (30.2%) | 11 (26.2%) | 2 (25%) | ||
Grade III | 73 | 5 (50%) | 31 (54.4%) | 35 (54.7%) | 2 (100%) | 77 | 15 (45.4%) | 32 (60.4%) | 28 (66.7%) | 2 (25%) | ||
Nodal status | 133 | 0.140 | 136 | 0.052 | ||||||||
Positive | 69 | 3 (30%) | 34 (59.6%) | 32 (50%) | 0 (0%) | 71 | 12 (36.4%) | 30 (56.6%) | 22 (52.4%) | 7 (87.5%) | ||
Negative | 64 | 7 (70%) | 23 (40.4%) | 32 (50%) | 2 (100%) | 65 | 21 (63.4%) | 23 (43.4%) | 20 (47.6%) | 1 (12.5%) | ||
ER-α | 133 | 0.005 | 136 | 0.005 | ||||||||
Positive | 91 | 9 (90%) | 45 (78.9%) | 37 (57.8%) | 0 (0%) | 93 | 24 (72.7%) | 43 (81.1%) | 20 (47.6%) | 6 (75%) | ||
Negative | 42 | 1 (10%) | 12 (21.1%) | 27 (42.2%) | 2 (100%) | 43 | 9 (27.3%) | 10 (18.9%) | 22 (52.4%) | 2 (25%) | ||
E-cadherin | 91 | 0.044 | 94 | <0.001 | ||||||||
Positive | 46 | 7 (77.8%) | 25 (58.1%) | 14 (37.8%) | 0 (0%) | 46 | 21 (80.8%) | 15 (41.7%) | 10 (38.5%) | 0 (0%) | ||
Negative | 45 | 2 (22.2%) | 18 (41.9%) | 23 (62.2%) | 2 (100%) | 48 | 5 (19.2%) | 21 (58.3%) | 16 (61.5%) | 6 (100%) | ||
P-cadherin | 131 | 0.128 | 134 | 0.173 | ||||||||
Positive | 43 | 2 (20%) | 16 (28.6%) | 23 (36.5%) | 2 (100%) | 45 | 9 (27.3%) | 15 (28.3%) | 19 (47.5%) | 2 (25%) | ||
Negative | 88 | 8 (80%) | 40 (71.4%) | 40 (63.5%) | 0 (0%) | 89 | 24 (72.7%) | 38 (71.7%) | 21 (52.5%) | 6 (75%) |
ctn, catenin; ER, oestrogen receptor; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.